Alto Neuroscience is a clinical-stage biopharmaceutical company leveraging a Precision Psychiatry Platform to develop personalized psychiatric treatment options. The company measures brain biomarkers through EEG activity, neurocognitive assessments, and wearable data to identify patients more likely to respond to Alto product candidates. Founded in 2019 by Dr. Amit Etkin after over a decade of clinical research at Stanford University, Alto went public on NYSE (ticker: ANRO) in February 2024, raising $147.9 million in gross proceeds.
Alto Neuroscience is publicly traded
IPO'd on Feb 6, 2024
This company is no longer available on our private secondary market. Shares can be traded publicly under ANRO.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2019
Employees
51–200
Total Funding
$145M
5 rounds
Closed $120M PIPE led by Commodore Capital at $20.00/share ahead of planned ALTO-207 Phase 3
Large post-IPO raise at higher share price signals improved sentiment and funds pivotal trial
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $145M across 5 rounds
Last updated 09-26-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Nov 21, 2023 | Series C | $45M | — | InVivium Capital |
| Jan 30, 2023 | Series B extension | $25M | — | Alpha Wave Ventures |
| Oct 25, 2022 | Series B | $35M | — | Lightswitch Capital, partners of Alkeon Capital |
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Axsome Therapeutics
Commercial-stage CNS biopharmaceutical company with approved and investigational therapies for major depressive disorder and other psychiatric and neurological conditions.
Neumora Therapeutics
Clinical-stage neuroscience company developing precision-medicine therapies for brain diseases, including major depressive disorder.
Compass Pathways
Clinical-stage biotechnology company developing a psilocybin-based therapy for treatment-resistant depression.
atai Beckley
Clinical-stage biopharmaceutical company developing psychedelic and related compounds for treatment-resistant depression and other mental health disorders.
Neurocrine Biosciences
Commercial-stage biopharmaceutical company with approved and pipeline therapies for neurological, neuroendocrine and psychiatric disorders, including schizophrenia.
AbbVie
Large-cap biopharmaceutical company with approved and investigational neuropsychiatry products, including therapies for major depressive disorder and schizophrenia.
Yes, Alto Neuroscience is publicly traded under the ticker symbol ANRO on the NYSE. The company went public in Feb 6, 2024.
Alto Neuroscience trades under the ticker symbol ANRO on the NYSE. It began trading in Feb 6, 2024.
Alto Neuroscience (ANRO on the NYSE) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ANRO to place an order.
Alto Neuroscience went public in Feb 6, 2024 via ipo. Alto Neuroscience completed its initial public offering on February 6, 2024, on the New York Stock Exchange under ticker symbol ANRO. The company offered 9,246,000 shares at $16 per share, raising gross proceeds of $147.9 million. The IPO was upsized from the original plan following strong investor demand. Trading began February 2, 2024, opening at $22 per share, well above the IPO price.
Alto Neuroscience raised $145M across 5 disclosed funding rounds prior to its public listing.
Alto Neuroscience was founded by Amit Etkin in 2019.
Alto Neuroscience is headquartered in Mountain View, CA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.